Skip to content
Review

Performance of a high-sensitivity troponin-based early rule-out pathway for suspected myocardial infarction.

Aug 2026 · Acta Cardiologica · pp. 1-8 · 1 citation · 9 references
Medicine

TL;DR

Among a selected cohort managed through a structured rapid-access chest pain outpatient service, 30-day type I MI rates were low across all SAMIE risk categories, and these findings should be considered hypothesis-generating and require validation in larger prospective studies.

Abstract

INTRODUCTION High-sensitivity cardiac troponins enable early rule-out of myocardial infarction (MI), but their effect on diagnostic specificity remains uncertain. We evaluated rates of type I MI and obstructive coronary artery disease (CAD) among patients triaged using the Suspected Acute Myocardial Infarction in Emergency (SAMIE) pathway.

Methods

A retrospective cohort study was conducted on patients presenting with chest pain to an Australian Health Service Emergency Department between February 2023 and December 2024. Patients were classified as low-risk (troponin <5 ng/L), intermediate-risk (troponin ≥5 ng/L and Δ troponin <3 ng/L), or high-risk (troponin ≥5 ng/L and Δ troponin ≥3 ng/L or above sex-specific thresholds). All patients underwent expedited outpatient review through a rapid-access cardiac clinic. The primary outcome was type I MI within 30 days. Secondary outcomes included positive stress echocardiography and obstructive CAD on invasive coronary angiography.

Results

Among 355 patients (mean age 59.4 ± 17.5 years), 64 (18.0%) were low-risk, 121 (34.1%) intermediate-risk, and 170 (47.9%) high-risk. The 30-day type I MI rate was 0.6% (two events), both occurring in the SAMIE high-risk group. Rates of obstructive CAD and positive stress echocardiography were similar across risk categories.

Conclusions

Among a selected cohort managed through a structured rapid-access chest pain outpatient service, 30-day type I MI rates were low across all SAMIE risk categories. Both events occurred in the SAMIE high-risk group. Given the small number of events, these findings should be considered hypothesis-generating and require validation in larger prospective studies.

View source

Similar papers

Sep 2026

Rapid myocardial infarction rule-out: A single high-sensitivity cardiac troponin I and T threshold strategy for the Chinese emergency department.

BACKGROUND High-sensitivity cardiac troponin (hs-cTn) discerns MI with high sensitivity, facilitating swift ED discharge. Yet, its application in Chinese cohorts is understudied. This study seeks optimal hs-cTnI and hs-cTnT thresholds for low-risk patient identification in Chinese EDs, utilizing Abbott and Roche assays...

Fang-Fang Yang, Ya-Hui Lin, Hong Zhan et al. · 0 citations
Open access Jan 2026

Diagnosis of myocardial infarction in early presenters using 1-hour delta of high sensitive Troponin I: a pilot study

Highlights • Early hscTrop I levels evaluated for NSTEMI diagnosis in non-CAD early presenters.• In this pilot study, a 1-hour absolute delta hs-cTnI of 4 ng/L showed 95% specificity for NSTEMI, though this finding requres validation.• Baseline hscTrop I < 3 ng/L achieved 86% NPV for ruling out early NSTEMI.• Delta hsc...

M. Jeraiby, Johar Iqbal, Ibrahim Ahmed Robadi et al. · 0 citations
Open access Aug 2026

Serial high-sensitivity troponin-T and risk of heart failure in individuals with suspected acute coronary syndrome.

AIMS To investigate the association between serial high-sensitivity cardiac troponin-T (hs-TnT) concentrations and subsequent heart failure in individuals presenting with suspected acute coronary syndrome (ACS). METHODS AND RESULTS Utilizing Danish nationwide registries, we identified individuals without known heart...

Philip Ahle Erichsen, Majid Afzal, Christina Byrne et al. · 1 citation
Open access Aug 2026

Evaluation of risk stratification at presentation using the Alinity high-sensitivity cardiac troponin I assay

Background: High-sensitivity cardiac troponin (hs-cTn) assays enable safe early discharge of patients at very low risk for myocardial infarction. We previously developed a single-sample rule-out pathway using the ARCHITECT hs-cTnI assay to risk stratify patients with suspected acute coronary syndrome. In a secondary an...

Z. Li, T. Fujisawa, O. Skadberg et al. · 0 citations
Review Open access Sep 2026

False-Positive Troponins: Clinical Misclassification, Delayed Recognition, and Health Care Costs in a Real-World Cohort.

BACKGROUND Cardiac troponin immunoassays are critical for diagnosing myocardial infarction. Up to 10% of elevated results may be falsely positive because of heterophile antibodies or macrotroponin complexes, leading to misdiagnoses. METHOD We conducted a retrospective cohort study at the Royal Melbourne Hospital, Aus...

Lu Teng, Preetha Thomas, E. Quine et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.